Stay up to date with the most current clinical evidence, biomarkers, and therapies in the evolving treatment landscape of inflammatory bowel disease to inform treatment decisions through: 1) a text module; 2) accompanying slides; 3) an expert-written ClinicalThought commentary.
Learning objectives:
Upon completion of this activity, participants should be able to:
- Detail available and emerging biomarkers and diagnostics informing treatment decisions in IBD
- Incorporate available biomarkers appropriately into clinical practice based on guideline recommendations and expert consensus
- Evaluate evidence for the utility of TL1A blockade in IBD treatment
Faculty:
Jordan E. Axelrad, MD, MPH, FACG
Assistant Professor
Gastroenterology
NYU Grossman School of Medicine
New York, New York, United States of America
Co-Director, Inflammatory Bowel Disease Center at NYU Langone Health
Associate Professor of Medicine
NYU Grossman School of Medicine
New York, New York
Supporters
This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.
Sponsor:
Provided by Clinical Care Options, LLC in partnership with the American Gastroenterological Association (AGA)
Release date: June 30, 2025
Expiration date: May 7, 2026
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Primary Author
Jordan E. Axelrad, MD, MPH, FACG: consultant/advisor/speaker: AbbVie, Abviax, Adiso, bioMérieux, Bristol Myers Squibb, Celltrion, Ferring, Fresenius, Janssen, Merck, Pfizer, Vedanta; researcher: BioFire Diagnostics, Genentech, Janssen.
The planners and content peer reviewers from Clinical Care Options, LLC and the American Gastroenterological Association (AGA) do not have any relevant financial relationships to disclose.
